Clinical Trial Update: A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS [Phase 1, Phase 2]

View source ↗

Summary

A Phase Ib/II multicenter open-label study of bemcentinib (BGB324) in acute myeloid leukemia or myelodysplastic syndromes has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Bemcentinib (bemcentinib)

Snippet

Sponsor: BerGenBio ASA | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-19